Tocotrienol regulates osteoclastogenesis in rheumatoid arthritis
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: The present study aimed to investigate whether tocotrienol regulates interleukin 17 (IL-17)-induced osteoclastogenesis in rheumatoid arthritis (RA). Methods: We evaluated the effect of tocotrienol on IL-17-induced receptor activator of nuclear factor kappa B ligand (RANKL) production using RA fibroblast-like synoviocyte (FLS), together with real-time polymerase chain reaction and enzyme- linked immunosorbent assay. Osteoclast differentiation was confirmed after culturing IL-17-treated RA FLS and Th17 cells with tocotrienol and monocytes. We analyzed the suppressive effect of tocotrienol on Th17 cells percentage or Th17-cytokine levels among peripheral blood mononuclear cells using flow cytometry. Results: We found that IL-17 stimulated FLS to produce RANKL and tocotrienol decreased this IL-17-induced RANKL production. Tocotrienol decreased the IL-17-induced activation of mammalian target of rapamycin, extracellular signal-regulated kinase, and inhibitor of kappa B-alpha. When monocytes were incubated with IL-17, RANKL, IL-17-treated FLS or Th17 cells, osteoclasts were differentiated and tocotrienol decreased this osteoclast differentiation. Tocotrienol reduced Th17 cell differentiation and the production of IL-17 and sRANKL; however, tocotrienol did not affect Treg cell differentiation. Conclusions: Tocotrienol inhibited IL-17- activated RANKL production in RA FLS and IL-17-activated osteoclast formation. In addition, tocotrienol reduced Th17 differentiation. Therefore, tocotrienol could be a new therapeutic choice to treat bone destructive processes in RA.
Abstract
Background/Aims: The present study aimed to investigate whether tocotrienol regulates interleukin 17 (IL-17)-induced osteoclastogenesis in rheumatoid arthritis (RA). Methods: We evaluated the effect of tocotrienol on IL-17-induced receptor activator of nuclear factor kappa B ligand (RANKL) production using RA fibroblast-like synoviocyte (FLS), together with real-time polymerase chain reaction and enzyme- linked immunosorbent assay. Osteoclast differentiation was confirmed after culturing IL-17-treated RA FLS and Th17 cells with tocotrienol and monocytes. We analyzed the suppressive effect of tocotrienol on Th17 cells percentage or Th17-cytokine levels among peripheral blood mononuclear cells using flow cytometry. Results: We found that IL-17 stimulated FLS to produce RANKL and tocotrienol decreased this IL-17-induced RANKL production. Tocotrienol decreased the IL-17-induced activation of mammalian target of rapamycin, extracellular signal-regulated kinase, and inhibitor of kappa B-alpha. When monocytes were incubated with IL-17, RANKL, IL-17-treated FLS or Th17 cells, osteoclasts were differentiated and tocotrienol decreased this osteoclast differentiation. Tocotrienol reduced Th17 cell differentiation and the production of IL-17 and sRANKL; however, tocotrienol did not affect Treg cell differentiation. Conclusions: Tocotrienol inhibited IL-17- activated RANKL production in RA FLS and IL-17-activated osteoclast formation. In addition, tocotrienol reduced Th17 differentiation. Therefore, tocotrienol could be a new therapeutic choice to treat bone destructive processes in RA.
참고문헌 (28)
- Harris ED Jr, "Rheumatoid arthritis. Pathophysiology and implications for therapy", N Engl J Med, 322, pp.1277~1289 (1990)
- Rosen CJ, "Mechanisms of disease: is osteoporosis the obesity of bone?", Nat Clin Pract Rheumatol, 2, pp.35~43 (2006)
- Bartok B, "Fibroblast-like synoviocytes : key effector cells in rheumatoid arthritis", Immunol Rev, 233, pp.233~255 (2010)
- Gravallese EM, "Bone destruction in arthritis", Ann Rheum Dis, 61(Suppl 2), pp.ii84~ii86 (2002)
- Lubberts E, "IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand", osteoprotegerin balance, 2003, pp.170, 2655~2662
- Jovanovic DV, "IL17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages", J Immunol, 160, pp.3513~3521 (1998)
- Kim KW, "Th17 cytokines regulate osteoclastogenesis in rheumatoid arthritis", Am J Pathol, 185, pp.3011~3024 (2015)
- Genovese MC, "A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors", Arthritis Rheumatol, 66, pp.1693~1704 (2014)
- Genovese MC, "Efficacy and safety of secukinumab in patients with rheumatoid arthritis : a phase II, dose-finding, double-blind, randomised, placebo controlled study", Ann Rheum Dis, 72, pp.863~869 (2013)
- Qureshi AA, "Inhibition of nitric oxide in LPS-stimulated macrophages of young and senescent mice by δ-tocotrienol and quercetin", Lipids Health Dis, 10, pp.239~ (2011)
- Yam ML, "Tocotrienols suppress proinflammatory markers and cyclooxygenase-2 expression in RAW264. 7 macrophages", Lipids, 44, pp.787~797 (2009)
- Qureshi AA, "Tocotrienols inhibit lipopolysaccharide-induced pro-inflammatory cytokines in macrophages of female mice", Lipids Health Dis, 9, pp.143~ (2010)
- Radhakrishnan A, "Effect of γ-tocotrienol in counteracting oxidative stress and joint damage in collagen-induced arthritis in rats", Exp Ther Med, 7, pp.1408~1414 (2014)
- Haleagrahara N, "Therapeutic efficacy of vitamin E δ-tocotrienol in collagen-induced rat model of arthritis", Biomed Res Int, 2014, pp.539540~ (2014)
- Ha H, "α-Tocotrienol inhibits osteoclastic bone resorption by suppressing RANKL expression and signaling and bone resorbing activity", Biochem Biophys Res Commun, 406, pp.546~551 (2011)
- Lee JH, "Trolox prevents osteoclastogenesis by suppressing RANKL expression and signaling", J Biol Chem, 284, pp.13725~13734 (2009)
- Brooks R, "Direct inhibition of osteoclast formation and activity by the vitamin E isomer gamma-tocotrienol", Int J Vitam Nutr Res, 81, pp.358~367 (2011)
- 김해림, "N-acetyl-l-cysteine controls osteoclastogenesis through regulating Th17 differentiation and RANKL in rheumatoid arthritis", The Korean Journal of Internal Medicine, 34(1), pp.210~219 (2019), 대한내과학회[DOI]
- Brentano F, "RNA released from necrotic synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via Toll-like receptor3", Arthritis Rheum, 52, pp.2656~2665 (2005)
- Kim SJ, "Identification of a novel toll-like receptor 7 endogenous ligand in rheumatoid arthritis synovial fluid that can provoke arthritic joint inflammation", Arthritis Rheumatol, 68, pp.1099~1110 (2016)
- Boyle WJ, "Osteoclast differentiation and activation", Nature, 423, pp.337~342 (2003)
- Qureshi AA, "δ-Tocotrienol feeding modulates gene expression of EIF2, mTOR, protein ubiquitination through multiple-signaling pathways in chronic hepatitis C patients", Lipids Health Dis, 17, pp.167~ (2018)
- Chang PN, "Evidence of gamma-tocotrienol as an apoptosis-inducing, invasion-suppressing, and chemotherapy drug-sensitizing agent in human melanoma cells", Nutr Cancer, 61, pp.357~366 (2009)
- Feldmann M, "The role of TNF alpha and IL-1 in rheumatoid arthritis", Curr Dir Autoimmun, 3, pp.188~199 (2001)
- McInnes IB, "Cytokines in the pathogenesis of rheumatoid arthritis", Nat Rev Immunol, 7, pp.429~442 (2007)
- Guo YJ, "Effect of Bizhongxiao decoction and its dismantled formulae on IL-1 and TNF levels in collagen-induced arthritis in rat synovial joints", Theor Biol Med Model, 9, pp.47~ (2012)
- Won-Seok Lee, "Atorvastatin inhibits osteoclast differentiation by suppressing NF-κB and MAPK signaling during IL-1β-induced osteoclastogenesis", The Korean Journal of Internal Medicine, 33(2), pp.397~406 (2018), 대한내과학회[DOI]
- Wu SJ, "Tocotrienol-rich fraction of palm oil exhibits anti-inflammatory property by suppressing the expression of inflammatory mediators in human monocytic cells", Mol Nutr Food Res, 52, pp.921~929 (2008)